Patents by Inventor Weiyi SITU

Weiyi SITU has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200038438
    Abstract: The present disclosure relates to an angstrom silver injection for a cancer inhibition, a preparation method and an application. A composition of the angstrom silver injection includes: angstrom-level elementary substance silver powder with a concentration between 0.005 g/L and 0.500 g/L, medicinal anhydrous fructose with a concentration between 0.5 g/L and 1.0 g/L; sterile distilled water with a. concentration between 998.500 g/L and 999.495 g/L. Tumor cell membrane surface has higher negative charge, and the increase of the negative charge on the membrane surface relates to acid mucopolysaccharide, DNA, and side chain charge of protein, especially to the increase or exposure of sialic acid. Angstrom silver and silver ions have positive charge to combine with the protein and nucleic acid molecule with negative charge inside and outside cells for interfering with synthesis of the protein and replication and transcription of the DNA to destroy normal life activity of cancerous cells.
    Type: Application
    Filed: June 20, 2018
    Publication date: February 6, 2020
    Inventors: Weiyi Situ, Hui Xie, Yang Wang, Rong Fan
  • Publication number: 20170119818
    Abstract: The present invention provided an anticancer nano-silver composition for the treatment of lung cancer. The composition contains spherical nano-silver powder 12-200 mg/kg, pharmaceutically acceptable dispersing agent carbomer 700-800 mg/kg, triethanolamine 700-800 mg/kg, glucose 2.8-3.2 g/kg, and purified water as the diluent; of the spherical nano-silver powder, the purity of silver is ?99.99% and the particle size is 1-5 nm. Experiments demonstrated that the anticancer nano-silver composition can be used to inhibit proliferation of the human non-small cell lung cancer A549, and cause all cells death. The nano-silver composition of the present invention can be used in the manufacture of medicaments and for the treatment of lung cancer.
    Type: Application
    Filed: May 8, 2015
    Publication date: May 4, 2017
    Applicant: CHANGSHA DIGU NANO BIOTECHNOLOGY CO., LTD.
    Inventors: Jinjun LIU, Weiyi SITU, Qiangbai LI